A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study)

D Price,1* S Musgrave,2 E Wilson,2 E Sims,2 L Shepstone,2 A Blyth,2 J Murdoch,3 M Mugford,2 E Juniper,4 J Ayres,5 S Wolfe,6 D Freeman,7 A Lipp,8 R Gilbert9 and I Harvey2

1Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK
2Norwich Medical School, University of East Anglia, Norwich, UK
3School of Nursing and Midwifery, University of East Anglia, Norwich, UK
4Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
5School of Health & Population Sciences, University of Birmingham, Birmingham, UK
6Thorpewood GP Surgery, Norwich, UK
7Sheringham Medical Practice, Norfolk, UK
8Great Yarmouth and Waveney Primary Care Trust, Norfolk, UK
9Castle GP Partnership, Norwich, UK

*Corresponding author

Executive summary

Health Technology Assessment 2011; Vol. 15: No. 21
DOI: 10.3310/hta15210

Health Technology Assessment
NIHR HTA programme
www.hta.ac.uk
Executive summary

Background

The role of leukotriene receptor antagonists is not clear for primary care asthma management of patients who are uncontrolled on short-acting β₂-agonists alone [British Thoracic Society (BTS) Guidelines step 2] or uncontrolled on low-dose inhaled corticosteroid (ICS) alone (BTS Guidelines step 3). Most clinical trials evaluating the role of leukotriene antagonists compared with conventional treatment (ICS as initial controller therapy at step 2, and long-acting β₂-agonist as add-on therapy to ICS at step 3) are short term in nature, are not representative of ‘real-life’ asthma populations and management in primary care, and do not include a full prospective cost evaluation.

Objective

The aim of our study was to evaluate, under real-life practice conditions in UK primary care, asthma-specific quality of life (QOL), markers of asthma control, and cost-effectiveness of commencing therapy with leukotriene antagonists compared with ICS as initial controller therapy and compared with long-acting β₂-agonist as add-on therapy for patients with uncontrolled asthma already receiving ICS. Comparisons were made in terms of short-term efficacy and longer-term effectiveness at 2 months and 2 years, respectively.

Methods

This study comprised two separate randomisations, thus two pragmatic randomised controlled trials, powered for equivalence, enrolling patients aged 12–80 years with asthma uncontrolled by (1) short-acting β₂-agonist (step 2) or (2) ICS (step 3) and a score of ≤6 points on the Mini Asthma Quality of Life Questionnaire (MiniAQLQ) (best score = 7) and/or ≥1 point on the Asthma Control Questionnaire (ACQ) (score of ≤0.75 denotes well-controlled asthma). Study visits were scheduled to coincide with routine patient follow-up as per usual care for asthma, and the study was conducted so as to minimally interfere with normal clinical practice.

Health-care providers and patients were aware of treatment allocations, while study data collection and statistical analyses were blinded.

The primary study outcome was the MiniAQLQ, a validated disease-specific asthma QOL scale, chosen because it captures outcomes of relevance to patients and their primary care providers and reflects asthma control. An analysis of covariance was used, with treatment as a fixed effect, and baseline value as covariate, to analyse MiniAQLQ scores at 2 months (the primary time point), examining efficacy, and 2 years, as a measure of effectiveness, using an intention-to-treat approach. A 95% confidence interval (CI) for the difference between treatment mean scores was derived. While the minimum clinically important difference for the MiniAQLQ score is 0.5, we conservatively defined equivalence as a difference of 0.3; thus, 95% CI of less than ±0.3.

Other outcome measures were two markers of asthma control: the validated ACQ, which evaluates symptoms of asthma and reliever treatment usage, and asthma exacerbations requiring oral steroid therapy or hospitalisation. Incremental cost-effectiveness approaches were used to study health-economic outcomes utilising NHS and societal costs with markers of disease control and disease-specific and generic health-related QOL [European Quality of life-5 Dimensions questionnaire (EQ-5D)], with calculation of quality-adjusted life-years (QALYs). Additional outcome measures included per cent predicted peak expiratory flow (%PPEF), Royal College of Physicians three (RCP3) asthma questions, Mini Rhinitis Quality of Life Questionnaire (mRQLQ), respiratory tract infections, and consultations for respiratory tract infection, and, for step 3 only, change in ICS dose.

Results

Six hundred and eighty-seven patients, recruited from 53 primary care practices, were randomised and 650 participants (95%) had evaluable data for the primary study outcome (145 leukotriene antagonist and 155 ICS for initial controller
therapy, and 169 leukotriene antagonist and 181 long-acting β₂-agonist as add-on therapy to ICS). Of those receiving initial controller therapy, 51% were women; the mean age was 46 years and 22% were current smokers. Of those receiving add-on therapy, 63% were women; the mean age was 50 years and 17% were current smokers.

All treatments were associated with substantial mean improvements in outcome measures with no significant between-group differences in MiniAQLQ or ACQ score or QALYs gained at 2 months and 2 years.

**Leukotriene antagonists compared with ICSs as initial controller therapy**

At 2 months, the MiniAQLQ scores met our equivalence criterion, with adjusted difference (95% CI) between leukotriene antagonist and ICS of −0.02 (−0.24 to 0.20). At 2 years, however, the 95% CIs excluded the threshold for equivalence of 0.3, favouring ICS [−0.11 (−0.35 to 0.13)]. No significant between-group differences were found in ACQ score at either 2 months [adjusted difference 0.01 (−0.20 to 0.22)] or 2 years [0.13 (−0.07 to 0.33)]. The 95% CIs were well within the minimum clinically important difference of 0.5 for the ACQ. No significant differences between leukotriene antagonist and ICS were found for any other secondary end point at 2 months or 2 years, including the number of asthma exacerbations, %PPEF, RCP3 questions, mRQLQ, respiratory tract infections or respiratory tract infection consultations.

**Leukotriene antagonist compared with long-acting β₂-agonist as add-on therapy to ICS**

At 2 months, the MiniAQLQ scores met our equivalence criterion, with adjusted difference (95% CI) between leukotriene antagonist and long-acting β₂-agonist of −0.10 (−0.29 to 0.10). At 2 years, the 95% CIs for MiniAQLQ score were marginally over the equivalence threshold, favouring long-acting β₂-agonist as add-on therapy [adjusted difference at 2 years −0.11 (−0.32 to 0.11)]. However, there were no significant between-group differences in ACQ score at either 2 months [0.12 (−0.06 to 0.30)] or 2 years [0.04 (−0.15 to 0.22)]. Daily ICS dose did not differ between the two treatment groups. No significant differences were found in exacerbations, %PPEF, RCP3 questions, or mRQLQ, respiratory tract infections or respiratory tract infection consultations.

**Cost-effectiveness results**

Compared with those receiving ICS as initial controller therapy, participants receiving leukotriene antagonist had significantly higher NHS and societal costs at both time points. ICS numerically dominated leukotriene antagonist in terms of cost-effectiveness, although outcomes were not statistically significantly different.

For patients receiving add-on therapy to ICS, no significant differences between leukotriene antagonist and long-acting β₂-agonist in NHS or societal cost were found at 2 months, but, after 2 years, participants receiving leukotriene antagonist had higher societal costs of borderline statistical significance. The extra cost per extra QALY gained was £22,589 (2-year time horizon, societal perspective). Given a willingness to pay of £30,000 per QALY gained, there is a probability of between 51.6% and 54.6% that leukotriene antagonist is a cost-effective alternative to long-acting β₂-agonist as add-on therapy to ICS, depending on time horizon and perspective.

The broad inclusion criteria for this study meant that active smokers, those with smaller impairments of lung function and patients with other comorbidities, who are typically excluded from clinical trials, were included in our study population. The conduct of this study in patients’ own primary care practices by their normal healthcare providers retained the ‘real-life’ setting, thereby enabling the generalisability of our results to primary care. This also resulted in extremely low dropouts from the study, which contrasts strongly with most published randomised trials in respiratory disease. A limitation of this study is that by 2 years many patients were switched from initial randomised therapy to alternate therapy due to a range of factors, including practice protocols for inhalers and chlorofluorocarbon transition. We speculate that another factor may be the shorter durations of drug supplies in those randomised to leukotriene antagonist and resulting greater review, providing greater opportunities to change therapy.

**Conclusions**

Results of this pragmatic trial in UK primary care were equivalent with regard to asthma-specific
Executive summary: An RCT of the use of LTRAs in primary care at steps 2 and 3 of the national asthma guidelines

QoL (MiniAQLQ) at 2 months after commencing controller therapy with leukotriene antagonist or ICS (step 2 of the BTS guidelines). Our equivalence criterion for MiniAQLQ was not met at 2 years; however, there were no statistically significant differences between treatment groups at this time. There were no differences in asthma control measures (ACQ score and exacerbations) at 2 months or 2 years; thus, any possible advantage of one over the other appears to be clinically unimportant. All treatments were associated with substantial mean improvements, which may, at least in part, have been due to regression to the mean or treatment effects. At 2005 UK prices of leukotriene antagonist and ICS, leukotriene antagonist was not a cost-effective alternative to inhaled corticosteroid at step 2.

Results of add-on therapy with leukotriene antagonist or long-acting β₂-agonist for patients with uncontrolled asthma already receiving ICS (step 3) were equivalent at 2 months (step 3 of the BTS guidelines), and at 2 years almost met our equivalence criterion. There were no significant differences between treatment groups in ACQ score or exacerbations. Leukotriene antagonist was of borderline cost-effectiveness compared with long-acting β₂-agonist.

Implications for health care

The evidence suggests that, while any advantage of one treatment over the other appears to be clinically unimportant, leukotriene antagonists are unlikely to be a cost-effective alternative to ICSs, at 2005 prices, as initial asthma controller therapy at step 2. In addition, the evidence suggests that leukotriene antagonists may be clinically equivalent to long-acting β₂-agonists as add-on to ICSs in terms of QOL, as well as secondary measures, and, furthermore, suggests that leukotriene antagonists could be repositioned as an equal alternative to long-acting β₂-agonists at step 3 of the BTS guidelines.

When generic leukotriene antagonist formulations become available in the next few years their cost-effectiveness as an alternative to ICS may justify further evaluation, particularly in the subgroup of patients with limited impairment of lung function, those newly diagnosed with asthma to minimise inhaler education and those with fears about inhalers or inhaled steroids.

Recommendations for research

- Establish, in primary care, whether leukotriene antagonists will be more or less beneficial than ICSs alone or as an add-on to ICSs in treating patients with asthma who are also active smokers.
- Determine why the ACQ correlates more poorly with economic outcomes of asthma than the MiniAQLQ and EQ-5D.
- Understand further the reasons why patients were switched from study medication when there was no real clinical indication to do so and examine ways to minimise this happening in future pragmatic primary care-based clinical trials.

Trial registration

This trial is registered as ISRCTN99132811.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Publication

How to obtain copies of this and other HTA programme reports

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:
– fax (with credit card details)
– post (with credit card details or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:
Synergie UK (HTA Department) Email: orders@hta.ac.uk
Digital House, The Loddon Centre Tel: 0845 812 4000 – ask for ‘HTA Payment Services’
Wade Road (out-of-hours answer-phone service)
Basingstoke
Hants RG24 8QW Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.

Paying by credit card
You can order using your credit card by phone, fax or post.

Subscriptions

NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?

Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned by the HTA programme as project number 98/34/05. The contractual start date was in October 2001. The draft report began editorial review in May 2007 and was accepted for publication in October 2009. As the funder, by devising a commissioning brief, the HTA programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley CBE
Series Editors: Dr Martin Ashton-Key, Professor Aileen Clarke, Professor Chris Hyde, Dr Tom Marshall, Professor John Powell, Dr Rob Riemsma and Professor Ken Stein
Associate Editor: Dr Peter Davidson
Editorial Contact: edit@southampton.ac.uk

© Queen’s Printer and Controller of HMSO 2011. This work was produced by Price et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (http://www.publicationethics.org/). This journal may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.

Applications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA.
Printed on acid-free paper in the UK by the Charlesworth Group.